Literature DB >> 21248442

Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast.

Dhanya S Palappallil1, Bindu Latha R Nair, K L Jayakumar, Ramani T Puvathalil.   

Abstract

CONTEXT: When cure is possible treatment should be undertaken despite life-threatening toxicities. Fluorouracil-Adriamycin-Cyclophosphamide (FAC) and Adriamycin-Cyclophosphamide (AC-P) are two popular regimens used in the treatment of carcinoma breast and the data regarding the toxicity profile of the AC-P regimen is scarce in the South Indian population. AIMS: To study the severity of different types of toxicities seen in patients on FAC and AC-P regimens, to grade the toxicity according to the World Health Organization (WHO) toxicity grading, and to compare the same. SETTINGS AND
DESIGN: A prospective observational study, with 50 patients in each regimen, was conducted in the Department of Radiotherapy between February 2007 and July 2008.
MATERIALS AND METHODS: The high risk patients received the AC-P regimen and the rest received the FAC regimen. The toxicities developed were graded according to the WHO guidelines. STATISTICAL ANALYSIS USED: The data was analyzed using the chi square test in SPSS 16.
RESULTS: Anemia, hyperpigmentation, stomatitis, and diarrhea were significantly high (P < 0.05) in patients receiving the FAC regimen, whereas, leukopenia, myalgia, arthralgia and peripheral neuropathy were significantly high (P < 0.05) in patients receiving the AC-P regimen. The Karnofsky performance status was higher in patients receiving the AC-P regimen.
CONCLUSIONS: Although both the regimens had different toxicity profiles the quality of life was better for patients on the AC-P regimen.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248442     DOI: 10.4103/0019-509X.75836

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  5 in total

1.  A Prospective Comparative Study of the Toxicity Profile of 5-Flurouracil, Adriamycin, Cyclophosphamide Regime VS Adriamycin, Paclitaxel Regime in Patients with Locally Advanced Breast Carcinoma.

Authors:  Jihana Shajahan; Pradeep Sadasivan Pillai; Krishnan Nair Lalithamma Jayakumar
Journal:  J Clin Diagn Res       Date:  2015-12-01

Review 2.  Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.

Authors:  Ricardo Fernandes; Sasha Mazzarello; Brian Hutton; Risa Shorr; Habeeb Majeed; Mohammed Fk Ibrahim; Carmel Jacobs; Michael Ong; Mark Clemons
Journal:  Support Care Cancer       Date:  2016-05-05       Impact factor: 3.603

Review 3.  Breast cancer: An overview of published Indian data.

Authors:  Bharath Rangarajan; Tanuja Shet; Tabassum Wadasadawala; Nita S Nair; R Madhu Sairam; Sachin S Hingmire; Jyoti Bajpai
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

4.  Severe oral mucositis relating to pain and worse oral condition among patients with solid tumors undergoing treatment with FOLFIRI and 5-FU: a retrospective study.

Authors:  Laura Costa de Almeida; Bernardo da Fonseca Orcina; Aloizio Premoli Maciel; Dayanne Dos Santos; Brena Rodrigues Manzano; Paulo Sérgio da Silva Santos
Journal:  Sao Paulo Med J       Date:  2022 Jul-Aug       Impact factor: 1.838

Review 5.  Chemotherapy protocols and incidence of oral mucositis. An integrative review.

Authors:  Marina Curra; Luiz Alberto Valente Soares Junior; Manoela Domingues Martins; Paulo Sérgio da Silva Santos
Journal:  Einstein (Sao Paulo)       Date:  2018-04-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.